VORVor Biopharma Inc.
$19.16-43% 1Y
$19.16
$6.8652 weeks$33.40
VOR as reported
- Net income
- $628M
Net income · −138% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$141M
Free cash flow · +23% year on year · trailing twelve months to Q2 2026
- EPS
- $179.71
EPS · −166% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | $628M | −138% | Q2 2026 |
| EPS | $179.71 | −166% | Q2 2026 |
| ROE | 202% | n/a | Q2 2026 |
| ROA | −396% | n/a | Q2 2026 |
| Free cash flow | −$141M | +23% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Vor Biopharma Inc. (VOR) · Net incomeNet incomeVor Biopharma Inc. (VOR)